BIOCRYST PHARMACEUTICALS INC Annual Report: Your 2025 Investor Overview

Welcome to your straightforward guide to BIOCRYST PHARMACEUTICALS INC's performance for the fiscal year ending December 31, 2025. This summary provides a clear picture for investors, highlighting key developments and financial results.

Business Overview

BIOCRYST PHARMACEUTICALS develops and commercializes medicines for rare diseases. Its flagship product, ORLADEYO (berotralstat), is an oral, once-daily treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. The company also markets RAPIVAB (an influenza treatment) and advances a pipeline of drugs in various stages of development for other rare conditions.

In fiscal year 2025, BioCryst saw robust growth in ORLADEYO sales, which drove overall revenue increases. Alongside this commercial success, the company made strategic adjustments, including divesting a non-core asset and focusing on cost management and operational efficiency.

Financial Performance

Let's examine the key financial figures for 2025 compared to previous years:

• Total Revenue:
  • Total revenue reached $360 million in 2025, a solid 15.4% increase from $312 million in 2024. This also represents a significant jump from $215 million in 2023, reflecting strong top-line growth.
• Product Sales (primarily ORLADEYO):
  • ORLADEYO remains the primary growth driver, generating $350 million in 2025. This is up 16.7% from $300 million in 2024 and a substantial increase from $200 million in 2023. This consistent growth highlights the drug's market acceptance.
  • Domestic (U.S.) sales grew from $200 million in 2024 to $250 million in 2025, while international sales remained steady at $100 million.
• License and Other Revenues:
  • This category, including income from licensing deals, decreased to $10 million in 2025, down from $12 million in 2024 and $15 million in 2023. This shift indicates a greater reliance on direct product sales for revenue generation.
• Cost of Goods Sold (COGS):
  • COGS totaled approximately $55 million in 2025, up from $48 million in 2024 and $35 million in 2023, reflecting increased product sales.
• Gross Profit:
  • Gross profit reached $305 million in 2025, compared to $264 million in 2024 and $180 million in 2023. The gross margin remained strong, reflecting healthy profitability on product sales.
• Operating Expenses:
  • Research and Development (R&D) expenses decreased to $150 million in 2025, down from $160 million in 2024 and $170 million in 2023. While this improves current profitability, it raises questions about long-term pipeline investment.
  • Selling, General, and Administrative (SG&A) expenses also decreased to $200 million in 2025, down from $210 million in 2024 and $220 million in 2023. This reflects a concerted effort to manage operational costs.
• Operating Loss:
  • Despite revenue growth and cost control, the company reported an operating loss of $50 million in 2025, an improvement from $96 million in 2024 and $190 million in 2023. This trend suggests the company is moving towards operational breakeven.
• Net Loss:
  • Factoring in interest expenses and other items, BioCryst reported a net loss of $80 million in 2025, an improvement from $100 million in 2024 and $130 million in 2023.
• Earnings Per Share (EPS):
  • The net loss resulted in an EPS of -$0.80 in 2025, compared to -$1.00 in 2024 and -$1.30 in 2023 (assuming approximately 100 million shares outstanding).
• Cash Flow from Operations:
  • Cash used in operations was $20 million in 2025, an improvement from $40 million in 2024 and $60 million in 2023, signaling improved efficiency in cash management.

Risk Factors

Investors should consider the following key risks:

• Heavy Reliance on ORLADEYO: The company overwhelmingly depends on ORLADEYO for revenue. New competitive treatments, safety concerns, payer pricing pressures, or intellectual property challenges could severely impact financial performance.
• High Debt and Royalty Obligations: Substantial debt, compounded by PIK interest, and significant royalty agreements mean a large portion of future ORLADEYO sales will service debt and royalty payments, rather than directly benefiting the company's cash flow or shareholders. This limits financial flexibility.
• Decreasing Cash Reserves and Liquidity Risk: Declining cash and short-term investments, coupled with negative operating cash flow, raise concerns about the company's long-term liquidity. If cash reserves deplete further, the company may need to raise additional capital, potentially through dilutive equity offerings or further debt, negatively impacting existing shareholders.
• Reduced R&D Spending and Pipeline Risk: While cost-cutting benefits short-term profitability, continuous R&D spending reductions could jeopardize new drug development. A robust pipeline is essential for a biotech company's long-term growth and sustainability. Clinical trials for pipeline drugs (e.g., BCX17725, Avoralstat, and Factor D Program) carry inherent failure risks, potentially impacting future revenue streams.
• Competition in the HAE Market: Despite ORLADEYO's strong performance, the HAE market remains competitive, with established players like Takeda (TAKHZYRO) and CSL Behring (Haegarda). New entrants or improved therapies could intensify competition, impacting ORLADEYO's market share and pricing power.
• Regulatory and Reimbursement Environment: Changes in healthcare laws, regulations, or reimbursement policies could negatively impact ORLADEYO's commercialization and pipeline product development.
• Intellectual Property Protection: The company's success depends on its ability to protect intellectual property. Patent challenges or an inability to secure new patents could expose the company to competition.

Management's Discussion and Analysis (MD&A) Highlights

In 2025, management focused on strategic execution to drive ORLADEYO's commercial success and improve financial efficiency. Robust ORLADEYO sales primarily drove the 15.4% total revenue increase, reflecting strong market acceptance and effective commercial strategies.

BioCryst optimized its structure and resource allocation through strategic streamlining, including divesting its BioCryst Ireland operations, which generated $5 million in license revenue. This, combined with significant R&D and SG&A expense reductions, highlights a concerted effort to manage operational costs and accelerate profitability. While these cost-cutting measures, including $5 million in severance costs from workforce reductions, improved the operating loss, management acknowledges the need to balance short-term profitability with long-term pipeline investment.

Despite these improvements, the company still reports a net loss and faces ongoing challenges from its substantial debt burden, including "Payment-in-Kind" (PIK) interest, and significant ORLADEYO royalty obligations. These financial structures demand careful cash management, especially given continued (though improving) operational cash burn and declining cash reserves. Management's strategy focuses on leveraging ORLADEYO's market position to generate sufficient cash flow for debt service and sustainable profitability, while prudently advancing key pipeline assets. The company also monitors external factors like payer scrutiny, the evolving rare disease regulatory landscape, and the broader biotech funding environment, all of which could impact future performance and strategic flexibility.

Financial Health

• Cash and Investments: Cash and short-term investments (including money market funds and government securities) decreased from $220 million at the end of 2024 to $180 million at the end of 2025. This reduction indicates ongoing cash burn, albeit at an improving rate, underscoring the importance of liquidity management.
• Substantial Debt Load: BioCryst carries a significant debt burden, totaling approximately $500 million at the end of 2025 (up from $450 million in 2024), primarily from loan agreements with partners like Pharmakon Advisors LP and Athyrium. A key feature is the "Payment-in-Kind" (PIK) interest option, which allows the company to add interest to the loan principal instead of paying cash. While this conserves immediate cash, it causes the total debt balance to grow, increasing future interest obligations. A significant portion of this debt matures in 2027 and 2028.
• Collateralized Assets: The company pledged assets worth $20 million in 2025 (down from $25 million in 2024) as collateral for its credit agreements. This ties up some assets as loan security, limiting unencumbered assets.
• Working Capital: The company maintains a negative working capital position, meaning current liabilities exceed current assets. This requires careful cash management to meet short-term obligations.

Future Outlook

• ORLADEYO Growth: The company anticipates continued strong ORLADEYO growth, projecting 2026 total revenue between $400 million and $420 million. However, investors should consider the impact of royalty agreements on net cash flow from these sales.
• Pipeline Development: Despite reduced R&D spending, BioCryst commits to advancing its pipeline. Key milestones include expected Phase 2 data for BCX17725 in late 2026, which could significantly drive value if positive.
• RAPIVAB Contract: The ongoing contract with the U.S. Department of Health and Human Services (HHS) for RAPIVAB provides a stable, though smaller, revenue stream.
• Path to Profitability: The company's strategic focus on cost control and ORLADEYO growth aims to achieve operational profitability soon, with R&D expenses projected between $140 million and $150 million in 2026.
• Strategic Priorities: The company's strategy centers on maximizing ORLADEYO's commercial potential, disciplined operating expense management, and selective pipeline investment to diversify future revenue streams.

Competitive Position

BIOCRYST's primary competitive strength is ORLADEYO's position as the first and only oral, once-daily preventative treatment for HAE. This offers a significant convenience advantage over injectable therapies, driving strong market adoption. Key competitors in the HAE prophylactic market include Takeda's TAKHZYRO (subcutaneous injection) and CSL Behring's Haegarda (subcutaneous injection).

Beyond ORLADEYO, BioCryst has a pipeline of drugs targeting other rare diseases:

• BCX17725: An oral Factor D inhibitor in Phase 2 development for complement-mediated kidney diseases.
• Avoralstat: Another oral HAE treatment candidate.
• Factor D Program: Broader research into complement-mediated diseases.

Successful development of these pipeline assets will be crucial for diversifying revenue and maintaining a competitive edge in the rare disease space. The company aims to differentiate itself through novel oral therapies offering improved patient convenience and potentially better safety profiles.